Summary by Futu AI
ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 3, 2024. The registration pertains to the resale of up to 478,600 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Series A-1 and Series B-1 warrants, which were part of a private placement that closed on August 2, 2024. ZyVersa Therapeutics will not receive any proceeds from the sale of shares by the selling stockholders. However, if all warrants are exercised in cash at an exercise price of $3.46 per share, the company may receive approximately $1,655,956 in gross proceeds. The company has undergone reverse-stock-splits on December 4, 2023, and April 25, 2024, and the share information in the prospectus has been adjusted accordingly. ZyVersa's common stock is listed on The Nasdaq Stock Market under the symbol 'ZVSA'. The last reported sale price of the common stock was $2.77 per share as of August 30, 2024.
